Quick Overview
BPC-157 and TB-500 are the two most discussed peptides in the tissue repair and recovery space. Both show promising results in animal studies for accelerating healing, but they work through fundamentally different mechanisms. Understanding those differences is key to deciding which — if either — might be relevant to your situation.
BPC-157 excels at localized tissue repair and gut healing, primarily through angiogenesis. TB-500 works more systemically through cell migration and anti-inflammatory mechanisms. Many self-experimenters use both together — a protocol known as the Wolverine Stack.
BPC-157: The Gastric Healer
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protein found in human gastric juice. It has been studied primarily for its effects on tissue repair, with a particularly strong body of evidence around tendon healing and gastrointestinal protection.
Its primary mechanisms in animal models include promoting new blood vessel formation at injury sites, modulating growth factor receptors, and reducing inflammatory markers. A unique advantage is its apparent oral bioavailability — unusual for a peptide.
For a comprehensive overview, see our complete BPC-157 guide.
TB-500: The Systemic Repair Signal
TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide that occurs naturally in nearly all human and animal cells. Thymosin Beta-4 is one of the most abundant intracellular proteins and plays a critical role in actin regulation — the protein that forms the structural framework of cells.
How TB-500 works
TB-500's mechanisms differ from BPC-157 in important ways. It primarily promotes cell migration by regulating actin, which allows cells to move to areas where they're needed for repair. It has strong anti-inflammatory properties that work systemically rather than locally. It upregulates proteins involved in tissue repair and remodeling throughout the body. And it promotes the formation of new blood vessels, similar to BPC-157 but through a different pathway.
Research highlights
Thymosin Beta-4 has actually been studied in human trials — more so than BPC-157. Clinical research has explored its use in corneal wound healing (with promising results in Phase II trials), cardiac repair after myocardial infarction, and chronic wound healing in dermatological applications.
In animal studies, TB-500 has shown effects on muscle repair after strain injuries, hair regrowth (observed as a side effect in skin healing studies), reduced inflammation in various tissue types, and improved flexibility and reduced scar tissue formation.
Head-to-Head Comparison
| Parameter | BPC-157 | TB-500 |
|---|---|---|
| Origin | Human gastric juice protein | Thymus gland protein (Thymosin Beta-4) |
| Size | 15 amino acids (~1,419 Da) | 43 amino acids (~4,963 Da) |
| Primary mechanism | Angiogenesis, growth factor modulation | Actin regulation, cell migration |
| Effect scope | More localized (especially injected) | More systemic |
| Best studied for | Tendons, gut, soft tissue | Muscle, cardiac, corneal repair |
| Oral bioavailability | Yes (appears to remain active orally) | No (injection or topical only) |
| Human clinical trials | None completed | Phase II trials (corneal healing) |
| Common dose range | 250–500 mcg/day | 2–2.5 mg, 2x/week |
| Typical cycle | 4–8 weeks daily | 4–6 weeks, loading then maintenance |
| WADA banned | Yes (2022) | Yes |
| Approximate cost | $30–60 per 5mg vial | $40–80 per 5mg vial |
Where BPC-157 has the edge
BPC-157 may be better suited for tendon and ligament injuries (Achilles, rotator cuff, patellar tendon), gastrointestinal issues (leaky gut, IBS symptoms, ulcers), localized injury repair when you know exactly where the problem is, and oral administration when injection isn't preferred.
Where TB-500 has the edge
TB-500 may be more appropriate for muscle strains and tears, systemic inflammation affecting multiple areas, conditions where cell migration is a bottleneck (chronic wounds), situations where more human clinical data is desired, and flexibility and mobility concerns.
Can You Combine Them?
This is one of the most common questions in the peptide space, and the combination even has its own nickname: the Wolverine Stack (named after the fictional character's regenerative abilities).
The theoretical rationale for combining BPC-157 and TB-500 is straightforward: they work through different mechanisms that may be complementary. BPC-157 promotes blood vessel formation to supply the injury site, while TB-500 promotes cell migration to bring repair cells to the area. Using both could potentially address healing from multiple angles simultaneously.
There are no published studies — even in animals — that specifically test the BPC-157 + TB-500 combination. The "stack" is based entirely on theoretical reasoning and anecdotal user reports. This doesn't mean it's ineffective, but it does mean we're in uncharted territory.
For a complete breakdown of the Wolverine Stack protocol, dosing, and user-reported results, see our dedicated Wolverine Stack guide.
Which One Should You Choose?
There's no universal answer, but here's a practical framework based on the available evidence and common use patterns.
Consider BPC-157 alone if your primary concern is a specific tendon or ligament injury, you're dealing with gut issues (IBD symptoms, gastric distress), you prefer oral supplementation over injections, or you want to start with a single compound to gauge your response.
Consider TB-500 alone if you're dealing with muscle injuries or strains, your issues are more systemic (multiple areas of inflammation), flexibility and scar tissue are primary concerns, or you value the (slightly) stronger human clinical evidence base.
Consider both together if you have a significant injury you want to address aggressively, you've tried one alone without satisfactory results, your injury involves multiple tissue types (muscle + tendon), or you're comfortable with the higher cost and complexity.
For detailed dosing information for either peptide, see our dosage guide.
FAQ
Can I mix BPC-157 and TB-500 in the same syringe?
Many users do mix them for a single injection. Both peptides are reconstituted with bacteriostatic water. There's no known chemical interaction between the two that would degrade either compound. That said, this practice hasn't been studied formally.
Do I need to cycle BPC-157 and TB-500?
There's no clinical data on whether cycling is necessary. The common anecdotal approach is to run a 4-8 week protocol, take 2-4 weeks off, then repeat if needed. Some users run BPC-157 continuously for gut support while cycling TB-500.
Are there any interactions or contraindications?
No drug interactions have been formally studied. Theoretically, because both peptides affect blood vessel formation and immune function, caution is warranted for individuals with active cancer, as angiogenesis could theoretically promote tumor growth. This is speculative but worth noting. As with any compound, consult a healthcare professional.
Is TB-500 the same as Thymosin Beta-4?
TB-500 is a synthetic fragment or analog of Thymosin Beta-4. Depending on the manufacturer, it may be the full 43-amino-acid sequence or a shorter active fragment. The terms are often used interchangeably in casual discussion, though they aren't strictly identical.